Previously submitted to: Interactive Journal of Medical Research (no longer under consideration since May 25, 2023)
Date Submitted: Apr 3, 2022
Open Peer Review Period: Apr 3, 2022 - Apr 11, 2022
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Reduction of SARS-CoV-2 Viral Load by Photodynamic Therapy (PDT) Verified by QPCR – A Novel Approach to Treat Patients in Early Infection Stages
ABSTRACT
Background:
The current Covid-19 pandemic is affecting the life of many people worldwide, and although the search for vaccines has made fast progress, there is at the moment no effective medication available. This article explores the usage of Riboflavin (Vitamin B2) in combination with blue and ultraviolet light, which is known to be one of the best photosensitzers for anti-viral Photodynamic Therapy (aPDT).
Objective:
----
Methods:
It proposes a new treatment system with a LASER/LED treatment device combined with blue and UVA light therapy. It is interventional non-randomized study in 140 subjects. Participants were allocated to receive either photodynamic therapy plus daily testing for 5 days or to receive conventional care plus testing. Viral load and clinical symptoms were measured at the start of the study and after 24, 48, 72, 96, 120 and 168 hours.
Results:
A simple Welch t-test for two samples indicate a difference of 6.68 thresholds in the means of viral load values, with a confidence interval of [5.2; 8.72], p<0.01. The same test shows no significance in the difference in the means of the control group.
Conclusions:
aPDT decreases viral load in patients in early stages of COVID-19. Clinical Trial: Study plan and design can be reviewd on link below of the study registration ISRCTN registry with study ID ISRCTN10839729 https://www.isrctn.com/ISRCTN10839729
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.